Kristian Reich

Company: MoonLake Immunotherapeutics AG

Job title: Chief Scientific Officer

Seminars:

From Scientific Insight to Clinical Results – the IL-17A & IL-17F Inhibiting Nanobody® Sonelokimab in Hidradenitis Suppurativa 2:00 pm

Unravelling the pathophysiology of HS lesions – evidence for a role of IL-17F in HS inflammatory lesions Why penetration matters – new concepts around immune hotspots in inflammatory skin diseases Translational validation – clinical data from a phase 2 study of the IL-17A and IL-17F inhibiting Nanobody® sonelokimab in HSRead more

day: Conference Day Two